AR065342A1 - Composiciones farmaceuticas que contienen fumarato de quetiapina - Google Patents

Composiciones farmaceuticas que contienen fumarato de quetiapina

Info

Publication number
AR065342A1
AR065342A1 ARP080100625A ARP080100625A AR065342A1 AR 065342 A1 AR065342 A1 AR 065342A1 AR P080100625 A ARP080100625 A AR P080100625A AR P080100625 A ARP080100625 A AR P080100625A AR 065342 A1 AR065342 A1 AR 065342A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
compositions containing
quetiapine fumarate
containing quetiapine
preparation
Prior art date
Application number
ARP080100625A
Other languages
English (en)
Inventor
Amenos Anna Ruiz
Perez Carmen Ubeda
Martin Ignacio Diez
Original Assignee
Lesvi Laboratorios Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38089224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lesvi Laboratorios Sl filed Critical Lesvi Laboratorios Sl
Publication of AR065342A1 publication Critical patent/AR065342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Gránulo para la preparacion de composiciones farmacéuticas, que comprende un nucleo que comprende quetiapina o una sal farmacéuticamente aceptable de la misma como principio activo y un agente aglutinante, y una capa de recubrimiento que comprendeun agente lubricante. Además, proporciona nuevas composiciones farmacéuticas solidas que contienen quetiapina así como también un procedimiento para su preparacion.
ARP080100625A 2007-02-14 2008-02-14 Composiciones farmaceuticas que contienen fumarato de quetiapina AR065342A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07380037A EP1958617B1 (en) 2007-02-14 2007-02-14 Pharmaceutical compositions containing quetiapine fumarate

Publications (1)

Publication Number Publication Date
AR065342A1 true AR065342A1 (es) 2009-06-03

Family

ID=38089224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100625A AR065342A1 (es) 2007-02-14 2008-02-14 Composiciones farmaceuticas que contienen fumarato de quetiapina

Country Status (9)

Country Link
US (1) US20080193527A1 (es)
EP (1) EP1958617B1 (es)
AR (1) AR065342A1 (es)
AT (1) ATE480227T1 (es)
CL (1) CL2008000454A1 (es)
DE (1) DE602007009036D1 (es)
ES (2) ES2352299T3 (es)
PT (1) PT1958617E (es)
WO (1) WO2008098969A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
WO2011154118A1 (en) * 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201104977A1 (tr) * 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
WO2013100879A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
CN104523600A (zh) * 2014-11-21 2015-04-22 哈尔滨圣吉药业股份有限公司 一种富马酸喹硫平缓释微丸及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) 1997-08-01 1997-10-08 Zeneca Ltd Process
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
EP1448169A1 (en) 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
IL164155A0 (en) 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
US7238686B2 (en) 2003-03-03 2007-07-03 Hetero Drugs Limited Polymorphs of quetiapine fumarate
ES2223294B2 (es) 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
CN101005829A (zh) * 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye

Also Published As

Publication number Publication date
CL2008000454A1 (es) 2008-05-23
ES2352299T3 (es) 2011-02-17
PT1958617E (pt) 2010-10-28
ES2315159B1 (es) 2009-12-22
US20080193527A1 (en) 2008-08-14
EP1958617A1 (en) 2008-08-20
EP1958617B1 (en) 2010-09-08
ES2315159A1 (es) 2009-03-16
ATE480227T1 (de) 2010-09-15
WO2008098969A1 (en) 2008-08-21
DE602007009036D1 (de) 2010-10-21

Similar Documents

Publication Publication Date Title
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
EP2078731A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
ZA200807778B (en) Reverse-Phase microcapsules for active ingredients, simplified process of manufacture thereof and combined formulations WDG-CS, ZC, EC-SC and CX
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
IL211940A (en) Akt and 70p 6s Kinase Inhibitors, Pharmaceutical Preparations Including Them and Their Use in the Manufacture of Medicines to Treat Multiple-Form Glyoblastoma
EP2377849A4 (en) COMPOUND FOR PREVENTING P53-SNAIL BINDING AND CANCER THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
EP1932522A4 (en) THERAPEUTIC AGENT FOR LIVER DISEASE CONTAINING 2-AMINO-1,3-PROPANEDIOL DERIVATIVE AS AN ACTIVE INGREDIENT AND ASSOCIATED THERAPEUTIC METHOD FOR LIVER DISEASE
ZA201004214B (en) Dipeptidyl peptidase-iv inhibiting compounds,methods of preparing the same,and pharmaceutical compositions containing the same as active agent
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
WO2010136508A3 (en) Stem cell targeting

Legal Events

Date Code Title Description
FB Suspension of granting procedure